Bridging from preclinical to clinical studies for tyrosine kinase inhibitors based on pharmacokinetics/pharmacodynamics and toxicokinetics/toxicodynamics

Drug Metabolism and Pharmacokinetics

Volumn 26, Issue 6, 2011, Pages 612-620

  Hoshino Yoshino, Azusa ^a,b   Kato, Motohiro ^b   Nakano, Kohnosuke ^b   Ishigai, Masaki ^b   Kudo, Toshiyuki ^a   Ito, Kiyomi ^a  

^a MUSASHINO UNIVERSITY   (Japan)

^b CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Bridging; Human clinical dose; Kinase inhibitors; PK PD; Prediction; TK TD

Indexed keywords

DASATINIB; ERLOTINIB; GEFITINIB; IMATINIB; LAPATINIB; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB;

AREA UNDER THE CURVE; ARTICLE; CANCER INHIBITION; CHRONIC MYELOID LEUKEMIA; DOG; DRUG EFFICACY; DRUG EXPOSURE; ENZYME INHIBITION; HAPLORHINI; HUMAN; IC 50; JAPAN; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; NONHUMAN; PHARMACODYNAMICS; SQUAMOUS CELL CARCINOMA; STEADY STATE; TOXICOKINETICS; TUMOR XENOGRAFT; VULVA CANCER;

EID: 84855247629     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-11-RG-043     Document Type: Article

References (39)

1. Gibbs, J. B.: Mechanism-based target identification and drug discovery in cancer research. Science, 287: 1969-1973 2000.
2. ICH. Harmonized Tripartite Guideline: nonclinical evaluation for anticancer pharmaceuticals S9 current step 4 version dated 29 October 2009. http://www.ich.org/LOB/media/MEDIA5785.pdf. Accessed 25 June 2010.
3. Evans, W. E. and Relling, M. V.: Clinical pharmacokinetics-pharmacodynamics of anticancer drugs. Clin. Pharmacokinet., 16: 327-336 1989.
4. Fuse, E., Kobayashi, S., Inaba, M., Suzuki, H. and Sugiyama, Y.: Application of pharmacokinetically guided dose escalation with respect to cell cycle phase specificity. J. Natl. Cancer Inst., 86: 989-996 1994.
5. Interview form of Dasatinib. http://www.sprycel.jp/pdf/sp_if101001.pdf. Accessed 28 June 2010.
6. Interview form of Erlotinib. http://chugai-pharm.jp/hc/ss/pr/onco/drug/tar_fil0150/if/index.html. Accessed 28 June date 2010.
7. Interview form of Gefitinib. http://med.astrazeneca.co.jp/product/IF/IRE/_IF.pdf. Accessed 28 June 2010.
8. Interview form of Imatinib. http://www.novartis.co.jp/product/gli/if/if/_gli0909.pdf. Accessed 28 June 2010.
9. Interview form of Lapatinib. http://glaxosmithkline.co.jp/clubdGSK/if/tykerb.html. Accessed 28 June 2010.
10. Interview form of Nilotinib. http://www.novartis.co.jp/product/tas/if/if/_tas1002.pdf. Accessed 28 June 2010.
11. Interview form of Sorafenib. http://www.bayer-hv.jp/hv/products/if/nex.pdf Accessed 28 June 2010.
12. Interview form of Sunitinib. https://pfizerpro.jp/documents/if/sut/sut01d_if.htm. Accessed 28 June 2010.
13. Pharmaceuticals and Medical Devices Agency PMDA Drug label Dasatinib approved on 01/2009. http://www.info.pmda.go.jp/approvalSrch/ApprovalSrch. Accessed 30 June 2010.
14. Pharmaceuticals and Medical Devices Agency PMDA Drug label Erlotinib approved on 10/2007. http://www.info.pmda.go.jp/approvalSrch/ApprovalSrch. Accessed 30 June 2010.
15. Pharmaceuticals and Medical Devices Agency PMDA Drug label Gefitinib approved on 07/2002. http://www.info.pmda.go.jp/approvalSrch/ApprovalSrch. Accessed 30 June 2010.
16. Pharmaceuticals and Medical Devices Agency PMDA Drug label Imatinib approved on 11/2001. http://www.info.pmda.go.jp/approvalSrch/ApprovalSrch. Accessed 30 June 2010.
17. Pharmaceuticals and Medical Devices Agency PMDA Drug label Lapatinib approved on 04/2009. http://www.info.pmda.go.jp/approvalSrch/ApprovalSrch. Accessed 30 June 2010.
18. Pharmaceuticals and Medical Devices Agency PMDA Drug label Nilotinib approved on 01/2009. http://www.info.pmda.go.jp/approvalSrch/ApprovalSrch. Accessed 30 June 2010.
19. Pharmaceuticals and Medical Devices Agency PMDA Drug label Sorafenib approved on 01/2008. http://www.info.pmda.go.jp/approvalSrch/ApprovalSrch. Accessed 30 June 2010.
20. Pharmaceuticals and Medical Devices Agency PMDA Drug label Sunitinib approved on 04/2008. http://www.info.pmda.go.jp/approvalSrch/ApprovalSrch. Accessed 30 June 2010.
21. Kretz, O., Weiss, H. M., Schumacher, M. M. and Gross, G.: In vitro blood distribution and plasma protein binding of the tyrosine kinase inhibitor imatinib and its active metabolite, CGP74588, in rat, mouse, dog, monkey, healthy humans and patients with acute lymphatic leukaemia. Br. J. Clin. Pharmacol., 58: 212-216 2004.
22. Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J. and Lydon, N. B.: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med., 2: 561-566 1996.
23. Moyer, J. D., Barbacci, E. G., Iwata, K. K., Arnold, L., Boman, B., Cunningham, A., DiOrio, C., Doty, J., Morin, M. J., Moyer, M. P., Neveu, M., Pollack, V. A., Pustilnik, L. R., Reynolds, M. M., Sloan, D., Theleman, A. and Miller, P.: Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res., 57: 4838-4848 1997.
24. Rusnak, D. W., Lackey, K., Affleck, K., Wood, E. R., Alligood, K. J., Rhodes, N., Keith, B. R., Murray, D. M., Knight, W. B., Mullin, R. J. and Gilmer, T. M.: The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor- derived cell lines in vitro and in vivo. Mol. Cancer Ther., 1: 85-94 2001.
25. Wakeling, A. E., Guy, S. P., Woodburn, J. R., Ashton, S. E., Curry, B. J., Barker, A. J. and Gibson, K. H.: ZD1839 Iressa: an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res., 62: 5749-5754 2002.
26. Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., Cao, Y., Shujath, J., Gawlak, S., Eveleigh, D., Rowley, B., Liu, L., Adnane, L., Lynch, M., Auclair, D., Taylor, I., Gedrich, R., Voznesensky, A., Riedl, B., Post, L. E., Bollag, G. and Trail, P. A.: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res., 64: 7099-7109 2004.
27. Yamaoka, K., Tanigawara, Y., Nakagawa, T. and Uno, T.: A pharmacokinetic analysis program multi for microcomputer. J. Pharmacobiodyn., 4: 879-885 1981.
28. Kola, I. and Landis, J.: Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov., 3: 711-715 2004.
29. Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R. and Talpaz, M.: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med., 344: 1038-1042 2001.
30. Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S. and Sawyers, C. L.: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med., 344: 1031-1037 2001.
31. Kantarjian, H., Giles, F., Wunderle, L., Bhalla, K., OöBrien, S., Wassmann, B., Tanaka, C., Manley, P., Rae, P., Mietlowski, W., Bochinski, K., Hochhaus, A., Griffin, J. D., Hoelzer, D., Albitar, M., Dugan, M., Cortes, J., Alland, L. and Ottmann, O. G.: Nilotinib in imatinib-resistant CML and Philadelphia chromosome- positive ALL. N. Engl. J. Med., 354: 2542-2551 2006.
32. Peng, B., Lloyd, P. and Schran, H.: Clinical pharmacokinetics of imatinib. Clin. Pharmacokinet., 44: 879-894 2005.
33. Ranson, M., Hammond, L. A., Ferry, D., Kris, M., Tullo, A., Murray, P. I., Miller, V., Averbuch, S., Ochs, J., Morris, C., Feyereislova, A., Swaisland, H. and Rowinsky, E. K.: ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J. Clin. Oncol., 20: 2240-2250 2002.
34. Kamath, A. V., Wang, J., Lee, F. Y. and Marathe, P. H.: Preclinical pharmacokinetics and in vitro metabolism of dasatinib BMS-354825: a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. Cancer Chemother. Pharmacol., 61: 365-376 2008.
35. Keam, S. J.: Dasatinib: in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. BioDrugs, 22: 59-69 2008.
36. Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Siebels, M., Negrier, S., Chevreau, C., Solska, E., Desai, A. A., Rolland, F., Demkow, T., Hutson, T. E., Gore, M., Freeman, S., Schwartz, B., Shan, M., Simantov, R. and Bukowski, R. M.: Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med., 356: 125-134 2007.
37. Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., van Kooten, M., Dediu, M., Findlay, B., Tu, D., Johnston, D., Bezjak, A., Clark, G., Santabarbara, P. and Seymour, L.: Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med., 353: 123-132 2005.
38. Geyer, C. E., Forster, J., Lindquist, D., Chan, S., Romieu, C. G., Pienkowski, T., Jagiello-Gruszfeld, A., Crown, J., Chan, A., Kaufman, B., Skarlos, D., Campone, M., Davidson, N., Berger, M., Oliva, C., Rubin, S. D., Stein, S. and Cameron, D.: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med., 355: 2733-2743 2006.
39. Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., Oudard, S., Negrier, S., Szczylik, C., Kim, S. T., Chen, I., Bycott, P. W., Baum, C. M. and Figlin, R. A.: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med., 356: 115-124 2007.